T1加权MRI预测超声上肝脏病灶可见性的效用:确定超声引导下经皮介入可行性的临床工具
本研究纳入2010至2013年间109例患者共177个肝脏局灶性病变,评估脂肪抑制T1加权梯度回波MRI预测腹部超声可见性的价值。结果显示69.5%(123/177)病灶超声可见,30.5%(54/177)不可见;MRI病灶大小(p<0.0001)及FS-T1W-GRE上与肝实质等信号(p=0.036,非脂肪肝者p=0.014)与超声不可见相关。作者认为这些结果对规划MRI检出病灶的超声引导经皮介入有提示意义。
要点
- FS-T1W-GRE上病灶与肝实质等信号者超声不可见风险更高,非脂肪肝者尤著(p=0.014)。
- MRI病灶大小与超声可见性相关(p<0.0001)。
- 肝脂肪变与超声不可见无关(p=0.67),病灶位置(段或包膜下)亦无关。
核心结论
- MRI上病灶大小及FS-T1W-GRE与肝实质等信号是超声不可见的关联因素,在非脂肪肝中尤为明显。
研究设计与样本
- 经IRB批准的2010至2013年研究,纳入109例患者(女性28.4%,年龄66.9±10.9岁)共177个肝脏局灶性病变(肝细胞癌132个、转移瘤44个、其他1个),均行MRI及前瞻性放射科医师操作的治疗规划超声;由一名盲法放射科医师评估MRI。
关键影像表现/征象
- MRI评估病灶大小与位置,并采用双回波T1W-GRE判断肝脂肪变,FS-T1W-GRE量化病灶相对肝脏的信号强度。
- 69.5%(123/177)病灶超声可见,30.5%(54/177)超声不可见。
- 38.4%(68/177)病灶在FS-T1W-GRE上与肝脏等信号。
- 20.2%(22/109)患者MRI显示肝脂肪变。
诊断标准与关键数值
- MRI病灶大小与超声可见性相关(p<0.0001)。
- FS-T1W-GRE等信号与超声不可见相关(p=0.036),非脂肪肝者中相关(p=0.014);脂肪肝者中无此关联(p=0.67)。
- 病灶位于段或包膜下与超声可见性无关(分别为p=0.29和p=0.25)。
临床应用与阅片要点
- 作者认为这些结果对规划MRI检出肝脏局灶性病变的超声引导经皮介入有提示意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To determine the utility of fat-suppressed T1-weighted gradient recalled echo (FS-T1W-GRE) MRI to predict visibility of focal liver lesions (FLL) on abdominal ultrasound (US).
MATERIALS AND METHODS: With IRB approval, between 2010 and 2013, 109 patients (28.4% females, age 66.9±10.9years) with 177 FLL (hepatocellular carcinoma=132, metastases=44, other=1) underwent MRI and prospective, radiologist-performed treatment-planning US (to determine eligibility for US-guided ablation). MRI examinations were reviewed by a blinded radiologist who assessed: a) size and location of FLL, b) presence of hepatic steatosis on dual-echo T1W-GRE, and c) quantitative signal intensity of FLL relative to liver on FS-T1W-GRE. Associations between MR imaging findings and visibility on US were assessed using independent t-tests and the chi-squares test.
RESULTS: 69.5% (123/177) FLL were identified with US and 30.5% (54/177) were not visible. Size of FLL on MRI was associated with visibility on US (p<0.0001) with no association between FLL visibility on US and segmental or subcapsular location (p=0.29 and p=0.25, respectively). 20.2% (22/109) patients had hepatic steatosis on MRI, which was not associated with non-visibility of FLL on US (p=0.67). 38.4% (68/177) FLL were isointense to liver on FS-T1W-GRE which was associated with non-visibility on US (p=0.036) particularly in non-steatotic livers (p=0.014).
CONCLUSION: FLL size and isointensity of FLL to liver parenchyma on FS-T1W-GRE MRI are associated with non-visibility on US, particularly in non-steatotic livers. These results have implications when planning US-guided percutaneous interventions of FLL detected with MRI.
引用
- Miao TL, Kielar AZ, Hibbert RM, et al. Utility of T1-weighted MRI as a predictor of liver lesion visibility on ultrasound: A clinical tool to determine feasibility of ultrasound-guided percutaneous interventions. Eur J Radiol. 2017. PMID: 28583643. doi:10.1016/j.ejrad.2017.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。